A股異動 | 蘇博特盤中漲9% 2021年度淨利潤預增15%-25%
格隆匯1月5日丨蘇博特(603916.SH)盤中漲9.33%,報27.78元,總市值116億元,股價創超1年新高。蘇博特1月4日發佈公吿,公司預計2021年度歸屬於上市公司股東的淨利潤與上年同期相比增加6610萬元到11020萬元,同比增加15%到25%。報吿期內,公司產品和技術創新成效凸顯,九系聚羧酸減水劑佔比持續提升,市場充分認可,功能性材料增速和佔比雙豐收,風電灌漿料、抗裂材料、交通工程材料市場應用進一步拓寬;顧問式營銷策略引領行業,提升了重大工程和基礎設施建設項目的貢獻度。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.